<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ion Beam Applications Sa — News on 6ix</title>
<link>https://6ix.com/company/ion-beam-applications-sa</link>
<description>Latest news and press releases for Ion Beam Applications Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ion-beam-applications-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683619db78dffbe2df13e893.webp</url>
<title>Ion Beam Applications Sa</title>
<link>https://6ix.com/company/ion-beam-applications-sa</link>
</image>
<item>
<title>IBA delivers strong FY 2025 results with solid execution in all segments</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-delivers-strong-fy-2025-results-with-solid-execution-in-all-segments-1</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-delivers-strong-fy-2025-results-with-solid-execution-in-all-segments-1</guid>
<pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
<description>Read the entire full-year 2025 results press release here Louvain-la-Neuve, Belgium, 27 March 2026 - IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong execution across the businesses. Robust commercial momentum, notably in Proton Therapy, resulted in a historic order intake and a new all-time high backlog. Delivered in line with guidance, the year marks continued progress in the execution of IBA’s strategic roadmap to the benefit of al</description>
</item>
<item>
<title>IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-launches-myqamatrixxair-to-advance-patientspecific-qa-in-particle-therapy-1</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-launches-myqamatrixxair-to-advance-patientspecific-qa-in-particle-therapy-1</guid>
<pubDate>Sat, 21 Mar 2026 14:30:00 GMT</pubDate>
<description>The first wireless ionization chamber array for particle therapy PSQA delivers fast, reliable verification for proton and carbon ion treatments, supporting emerging techniques such as FLASH and ARC radiotherapy. Louvain-la-Neuve, Belgium, 21 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA MatriXX AiR, a high resolution, wireless 2D ion</description>
</item>
<item>
<title>Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/telix-selects-iba-cycloner-kiube-to-support-manufacturing-expansion-in-the-us-1</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/telix-selects-iba-cycloner-kiube-to-support-manufacturing-expansion-in-the-us-1</guid>
<pubDate>Fri, 20 Mar 2026 06:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies</description>
</item>
<item>
<title>IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-and-shreeji-sign-multisite-agreement-for-four-cyclotrons-to-expand-pet-radiopharmaceutical-manufacturing-across-india-1</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-and-shreeji-sign-multisite-agreement-for-four-cyclotrons-to-expand-pet-radiopharmaceutical-manufacturing-across-india-1</guid>
<pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-energy Cyclone® KIUBE 300 cycl</description>
</item>
<item>
<title>IBA – ACQUISITION OF OWN SHARES</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-acquisition-own-shares-170000989</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-acquisition-own-shares-170000989</guid>
<pubDate>Mon, 16 Feb 2026 17:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium, February 16th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Sept</description>
</item>
<item>
<title>IBA – Share buyback</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-share-buyback-170000600</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-share-buyback-170000600</guid>
<pubDate>Mon, 02 Feb 2026 17:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium, February 2nd, 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, effective as of February 3rd, 2026, in application of article 7:215 of the Belgian Companies and Associations Code. By a decision of the Board of Directors of March 18th, 2025, approving the Stock Option Plan 2025, and pursuant to the authorization given by the EGM of September 4th, 2023,</description>
</item>
<item>
<title>IBA signs contract for a Proteus®ONE proton therapy system to be located at the MacKay Memorial Hospital in New Taipei City, Taiwan</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-signs-contract-proteus-one-060000437</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-signs-contract-proteus-one-060000437</guid>
<pubDate>Tue, 27 Jan 2026 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, January 27, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus®ONE system in Taiwan, further reinforcing IBA’s</description>
</item>
<item>
<title>IBA – TRANSPARENCY NOTIFICATION</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-transparency-notification-170000821</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-transparency-notification-170000821</guid>
<pubDate>Wed, 21 Jan 2026 17:00:00 GMT</pubDate>
<description>(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 21, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 13, 2026. In its notification, Va</description>
</item>
<item>
<title>IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-selected-md-anderson-cancer-060000746</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-selected-md-anderson-cancer-060000746</guid>
<pubDate>Mon, 19 Jan 2026 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announced that it has signed a contract with the University of Texas MD Anderson Cancer Center, ranked #1 in cancer care by U.S. News & World Report, to re-equip and modernize its existing Proton Therapy Center in Houston with three state-of-the-art Proteus®ONE1 systems. IB</description>
</item>
<item>
<title>IBA signs contract for a three-room Proteus®PLUS solution to be installed at the Seoul St. Mary’s Hospital</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-signs-contract-three-room-060000031</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-signs-contract-three-room-060000031</guid>
<pubDate>Fri, 26 Dec 2025 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, December 26, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Catholic University of Korea, Seoul St. Mary’s Hospital, one of the largest hospital in South Korea, for a Proteus®PLUS1 solution to be installed in Seoul. The contract includes the equipment of a Proteus®PLUS solutio</description>
</item>
<item>
<title>IBA acquires ORA expanding its strategic leadership in Nuclear Medicine</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-acquires-ora-expanding-strategic-060000802</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-acquires-ora-expanding-strategic-060000802</guid>
<pubDate>Fri, 19 Dec 2025 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and mor</description>
</item>
<item>
<title>Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/proton-therapy-standard-care-patients-060000512</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/proton-therapy-standard-care-patients-060000512</guid>
<pubDate>Mon, 15 Dec 2025 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. This study, led by MD Anderso</description>
</item>
<item>
<title>China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/china-gold-irradiation-introduces-iba-060000948</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/china-gold-irradiation-introduces-iba-060000948</guid>
<pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in China, to install a Rhodotron® in Jiaxing, Zhejiang Province, as a first step of the transition of China’s irradiation processing industry to a new s</description>
</item>
<item>
<title>YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/yas-healthcare-signs-contract-proteus-060000403</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/yas-healthcare-signs-contract-proteus-060000403</guid>
<pubDate>Mon, 08 Dec 2025 06:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, December 8, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today it has signed a contract with YAS Healthcare, a subsidiary of DAS Holding, to install a Proteus®ONE1 compact proton therapy solution to be located in Dubai, United Arab Emirates (UAE). With the acquisition of this Proteus®ONE system, YAS Healthcare wil</description>
</item>
<item>
<title>Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/third-quarter-2025-iba-highly-060000297</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/third-quarter-2025-iba-highly-060000297</guid>
<pubDate>Thu, 20 Nov 2025 06:00:00 GMT</pubDate>
<description>Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025. Group Overview Equipment order intake at €195 million as of Q3 2025 (+6% vs. last year) with a strong contribution from IBA Technologies (+22%) driven by RadioPharma Solutions, and four Proteus®ONE solutions sold within IBA Clinical. Equipment and Services backlog stable at €1.3 billion, with sustained backlog</description>
</item>
<item>
<title>IBA – Regulated information</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-regulated-information-170000345</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-regulated-information-170000345</guid>
<pubDate>Fri, 07 Nov 2025 17:00:00 GMT</pubDate>
<description>November 7th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of securities conferring the rig</description>
</item>
<item>
<title>IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-integrates-artificial-intelligence-quality-060000253</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-integrates-artificial-intelligence-quality-060000253</guid>
<pubDate>Mon, 03 Nov 2025 06:00:00 GMT</pubDate>
<description>Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Founded in 2018 by Dr. Paul Jahnke</description>
</item>
<item>
<title>IBA opens the world of science and technology to secondary school girls</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-opens-world-science-technology-050000984</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-opens-world-science-technology-050000984</guid>
<pubDate>Fri, 17 Oct 2025 05:00:00 GMT</pubDate>
<description>Its Innovat’her event brought together female students to explore careers in STEM Louvain-la-Neuve, Belgium, October 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted the Innovat’her event yesterday, aimed at girls in their fifth and sixth years of secondary school. The goal was to introduce them to scientific and technical careers, which remain underrepresented in the academic choices of female students. The event welcomed 25 stud</description>
</item>
<item>
<title>IBA reports strong Half Year 2025 results, transforming towards a more profitable business</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/iba-reports-strong-half-2025-050000673</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/iba-reports-strong-half-2025-050000673</guid>
<pubDate>Thu, 28 Aug 2025 05:00:00 GMT</pubDate>
<description>Read the entire half year 2025 results press release here Louvain-la-Neuve, Belgium, 28 August 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2025. High revenue growth and improved profitability in H1 driven by accelerated backlog conversion Net sales rose 40% vs. H1 2024, to EUR 304.9 million, with IBA Clinical and IBA Technologies increasing by 47% and 30% respectively thanks to well-ex</description>
</item>
<item>
<title>Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution</title>
<link>https://6ix.com/company/ion-beam-applications-sa/news/heidelberg-university-hospital-expands-particle-050000631</link>
<guid isPermaLink="true">https://6ix.com/company/ion-beam-applications-sa/news/heidelberg-university-hospital-expands-particle-050000631</guid>
<pubDate>Wed, 20 Aug 2025 05:00:00 GMT</pubDate>
<description>Louvain-La-Neuve, Belgium, August 20, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer and Heidelberg University Hospital (Universitätsklinikum Heidelberg AöR, UKHD) announce today that they have signed a contract to install a Proteus®ONE1 compact proton therapy solution to be located on the University campus in Heidelberg, Germany. The first payment has</description>
</item>
</channel>
</rss>